Peptide Initiative

Peptides · Peptide comparison

Crystagen vs Vilon

Immunogeroprotective tripeptide bioregulator (Glu-Asp-Pro) that optimally stimulates thymic epithelial cell proliferation at 200 ng/mL, suppresses thymocyte apoptosis through p53 downregulation and Ki-67 upregulation, and contributed to a 4.1-fold mortality reduction in a 266-person 6-8 year clinical study when combined with complementary pineal peptides

Immunomodulatory dipeptide bioregulator (Lys-Glu) that upregulates SIRT1 expression 6-fold through direct DNA promoter binding, activates T-cell differentiation via sphingomyelin signaling, and reduces pro-inflammatory cytokines by up to 6-fold as a natural inducer of TNF tolerance

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangeCrystagen200–400 mcgVilon500–500 mcg
FrequencyCrystagenOnce dailyVilonOnce daily
AdministrationCrystagenSubcutaneous injectionVilonSubcutaneous injection
Cycle lengthCrystagen8-12 weeksVilon12+ weeks
Onset speedCrystagenGradual (3-4 weeks)VilonGradual (3-4 weeks)
Evidence levelCrystagenLimited human trialsVilonLimited human trials

Efficacy

Benefit ratings

Immune Rejuvenation

Crystagen94%
VilonNo recorded rating

Healthy Aging

Crystagen91%
Vilon91%

Cancer Defense

Crystagen85%
VilonNo recorded rating

Immune System Revival

CrystagenNo recorded rating
Vilon94%

Digestive Support

CrystagenNo recorded rating
Vilon82%

Technical data

Compound specifications

Crystagen

Molecular formula
C14H21N3O8
Molecular weight
359.3 g/mol
Half-life
Short plasma half-life typical of tripeptides (minutes); biological effects persist for weeks to months through gene expression modifications and thymic microenvironment restoration; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1/POT and LAT carrier families) when administered orally; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to ultra-short tripeptide structure
CAS number
Not assigned (patented as immunogeroprotective peptide, US8057810B2)

Vilon

Molecular formula
C11H21N3O5
Molecular weight
275.3 g/mol
Half-life
Short plasma half-life typical of dipeptides (minutes); biological effects persist for weeks to months through epigenetic modifications to SIRT1/PARP gene expression; metabolized to constituent amino acids
Bioavailability
Absorbed via intestinal peptide transporters (PepT1) when administered orally (demonstrated in animal studies); rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to ultra-short dipeptide structure
CAS number
45234-02-4

Protocols

Dosing compared

Crystagen

Subcutaneous

  • 200-400 mcgOnce daily · 10-20 days per course, repeated every 4-6 monthsFor the synthetic peptide form, a dose commonly used in research practice given as an injection under the skin. [6]

Intramuscular

  • 200-400 mcgOnce daily · 10-20 days per course, repeated every 4-6 monthsCan also be given as an intramuscular injection at a similar dose, used in research practice. [6]

Oral

  • 1-2 capsules (10 mg each)1-2 times daily with meals · 10-30 day course, repeated every 4-6 monthsThe oral capsule plan used in practice. Each Cytogen capsule holds 10 mg, delivering about 200-400 mcg of active peptide per dose. [6]

Vilon

Subcutaneous injection

  • 200–500 mcgOnce daily · 5–10 day courseCommon Khavinson-style introductory protocol for the KE (Lys-Glu) immune bioregulator; courses repeated 2–3 times yearly [6]. Research use only — no approved product.
  • 500 mcgOnce daily · 10–12 day courseTypical full-course practice dose; cycle repeated every 3–6 months [6].

Intramuscular injection

  • 500 mcgOnce daily · 10–12 day courseIntramuscular delivery is also documented for the injectable KE bioregulator; same per-course dosing as subcutaneous [6].

Applications

Best suited for

Crystagen

Restoring thymic function and immune competence in aging individuals with immune senescence
Crystagen is particularly well-suited for individuals focused on restoring thymic function and immune competence in aging individuals with immune senescence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
Crystagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for immune and anti-aging support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting immune function during and after illness recovery
Crystagen is particularly well-suited for individuals focused on supporting immune function during and after illness recovery. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence
Crystagen is particularly well-suited for individuals focused on geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Vilon

Immune system restoration in aging individuals with declining thymic function
Vilon is particularly well-suited for individuals focused on immune system restoration in aging individuals with declining thymic function. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Adjunctive immunomodulatory support during cancer treatment protocols
Vilon is particularly well-suited for individuals focused on adjunctive immunomodulatory support during cancer treatment protocols. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity
Vilon is particularly well-suited for individuals focused on geroprotective therapy targeting sirt1/parp pathways for cellular longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Comprehensive Khavinson bioregulator protocols for anti-aging and immune support
Vilon is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols for anti-aging and immune support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Crystagen

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Minor digestive changes

Uncommon

  • Flu-like symptoms

Serious

  • No documented serious adverse effects

Vilon

Common

  • Injection site reaction
  • Mild fatigue
  • Mild headache
  • Digestive changes

Uncommon

  • Flu-like symptoms

Serious

  • No documented serious adverse effects

Research status

Safety & evidence

Crystagen

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Crystagen is a crystalline protein extract (likely containing collagen-derived peptides) from animal tissues that is not FDA-approved and has essentially no published safety data in medical literature. As an undefined and poorly characterized biological mixture, batch consistency, sterility, and identity cannot be verified. Potential risks include allergic reactions to animal proteins, contamination from source tissues, and unknown immunological effects. No formal safety assessments, animal studies, toxicology screening, or human clinical trials exist. The product appears to exist primarily in Russian medical markets, and little information about its actual composition or manufacturing is publicly available.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (glutamic acid, aspartic acid, proline)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active autoimmune disease in flare without physician supervision
  • Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Vilon

Evidence level
Limited human trials
FDA status
Research compound
Safety overview
Vilon (immunomodulatory thymic peptide complex from bovine thymus) demonstrates favorable safety in Russian/Eastern European medical use over 20+ years with minimal documented serious adverse events in published literature. Bovine-derived peptide preparations carry theoretical prion disease risk (variant Creutzfeldt-Jakob disease) though processing methods and regulatory standards substantially reduce this risk. Common adverse effects are mild—local injection site reactions, transient fever, or lymphadenopathy—consistent with immune system stimulation rather than toxicity.

Contraindications

  • Known hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid)
  • Pregnancy and breastfeeding — insufficient reproductive safety data
  • Active autoimmune disease in flare without medical supervision
  • Organ transplant recipients on immunosuppression — potential interference with immunosuppressive regimens

Decision guide

Which is right for you?

Crystagen

Choose Crystagen if…

  • Restoring thymic function and immune competence in aging individuals with immune senescence
  • Comprehensive Khavinson bioregulator protocols for immune and anti-aging support
  • Supporting immune function during and after illness recovery
  • Geroprotective immunomodulation to extend healthspan and reduce age-related disease incidence

Vilon

Choose Vilon if…

  • Immune system restoration in aging individuals with declining thymic function
  • Adjunctive immunomodulatory support during cancer treatment protocols
  • Geroprotective therapy targeting SIRT1/PARP pathways for cellular longevity
  • Comprehensive Khavinson bioregulator protocols for anti-aging and immune support